WallStSmart

Merck & Company Inc (MRK)vsTelix Pharmaceuticals Limited (TLX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 8082% more annual revenue ($65.77B vs $803.79M). MRK leads profitability with a 13.6% profit margin vs -0.9%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

TLX

Avoid

27

out of 100

Grade: F

Growth: 8.0Profit: 3.5Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: 1.01
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for TLX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

TLX1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
49.3%10/10

Revenue surging 49.3% year-over-year

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

TLX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
6.3%3/10

ROE of 6.3% — below average capital efficiency

Operating MarginProfitability
1.9%3/10

Operating margin of 1.9%

Debt/EquityHealth
1.263/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : TLX

The strongest argument for TLX centers on Revenue Growth. Revenue growth of 49.3% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : TLX

The primary concerns for TLX are EPS Growth, Return on Equity, Operating Margin.

Key Dynamics to Monitor

MRK profiles as a value stock while TLX is a hypergrowth play — different risk/reward profiles.

TLX carries more volatility with a beta of 0.59 — expect wider price swings.

TLX is growing revenue faster at 49.3% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Telix Pharmaceuticals Limited

HEALTHCARE · BIOTECHNOLOGY · USA

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company is headquartered in North Melbourne, Australia.

Want to dig deeper into these stocks?